When Dr. Joshua Ishal got his 5- and 7-year-old daughters their first doses of the Covid-19 vaccine last week in Queens, he joined millions of other parents in protecting their 5- to 11-year-old children since the Pfizer-BioNTech vaccine was authorized for this age group in late October.
Dr. Ishal, a dentist who lives in Great Neck, N.Y., never questioned whether he would get his children vaccinated, but he has been wavering over the timing of their second shots.
The clinical trials that tested the Pfizer vaccine separated the doses by three weeks, which is why the U.S. Centers for Disease Control and Prevention recommends that interval. But emerging data suggests that a longer wait bolsters the immune response in the long run. What’s more, the extra time may reduce the risk of myocarditis — heart inflammation — a rare but serious side effect of the mRNA vaccines in adolescents and younger adults.
Health authorities in Canada recommend that children wait at least eight weeks between doses. In Britain, kids wait 12 weeks for the second shot.
Still, the potential benefits of waiting for the second dose must be balanced against the real risks of catching and spreading Covid during the wait. With the United States on the cusp of another major wave of cases and the new Omicron variant spreading rapidly, delaying means leaving children vulnerable to infection and illness for longer.
“I think that’s a hard call,” said Aubree Gordon, an infectious disease epidemiologist at the University of Michigan School of Public Health.
Is it more important for children to have good protection sooner? Or a better, more lasting protection later? The conundrum reminds Dr. Ishal of an episode of Seinfeld in which Jerry tells a story about picking a cold medicine from a wall of options at the drugstore. “This is quick acting, but this is long-lasting,” Jerry said. “When do I need to feel good, now or later?”
Trish Johnson, a financial adviser in Oakland, plans to push her son’s second dose back to six or even eight weeks. She has been swayed, she said, by the studies showing that a longer interval between doses leads to a better immune response.
“I’ve taken it upon myself, especially during this later part of the pandemic, to follow doctors on Twitter and do my own investigation,” she said. Almost two years into the pandemic, she feels that public health officials are taking too many precautions and failing to adapt to changing data. “That doesn’t work for me anymore,” she said.
Many experts agree that three weeks between doses is too short an interval for an optimal immune response.
“From an immunological standpoint, it makes more sense to wait,” said Deepta Bhattacharya, an immunologist at the University of Arizona. Pfizer didn’t choose three weeks between doses because it was the perfect interval. That decision, he said, “was more about public health and reducing community transmission, and completing this process quickly.” Dr. Bhattacharya plans to hold off on a second dose for his children until eight weeks.
The immune system needs time to ramp up after that first dose. Immune cells in the blood, known as B cells, can start producing antibodies within a week. But to generate really high-quality antibodies, those cells need to go through an intense kind of training camp inside the lymph nodes, and that process takes more than three weeks.
“You need them to sweat a little bit, those B cells,” said Andrés Finzi, an immunologist at the University of Montreal.
Much of the research on different dosing intervals comes from countries, like Canada and Britain, that opted to wait on the second shot for adults when vaccine doses were scarce last winter and spring. Dr. Finzi and his colleagues examined the immune response in 26 people who received their second shots three months or more after their first. They also looked at responses in 12 people who received their shots four weeks apart. The two groups produced roughly the same quantity of antibodies, but the group with a longer interval between doses produced stronger antibodies with a greater capacity to latch onto the virus and stay there.
In Britain, officials lengthened the dose interval for all vaccines to 12 weeks last December. Researchers at the University of Oxford studied hundreds of health workers who had received second doses before or after that policy took effect.
Their study found that people who waited 10 weeks between their first and second doses had antibodies levels about twice as high as those who only waited three or four weeks. Those antibodies are produced by B cells, which continue to develop over that long interval.
“It seems that giving the second dose at three to four weeks is just a bit too soon for your B cells to be ready to receive that boost,” said Susanna Dunachie, an immunologist at the University of Oxford, who led the study. What’s more, the longer dose interval also affected T cells, which help ramp up the body’s immune response. After the long interval, the T cells of study participants produced greater quantities of interleukin-2, a chemical signal that helps long-term immune memory.
“We were quite surprised,” Dr. Dunachie said.
She added, however, that a more robust immune response measured in the laboratory would not necessarily translate to better protection in the real world.
The Coronavirus Pandemic: Key Things to Know
A new U.S. surge. The C.D.C said that the Omicron variant’s rapid spread in the U.S. may portend a surge in infections as soon as January, but cases are already spiking, leading offices to cancel holiday parties, Broadway performances to be shuttered and college finals to be moved online.
The Omicron variant. The new Covid variant has been detected in dozens of countries. While Omicron appears to be able to partially evade antibodies, it could be less severe than other forms of the virus, and new laboratory studies indicate that vaccines, and especially boosters, may offer protection against severe disease.
Biden’s vaccine mandate. A federal appeals panel on Dec. 17 reinstated a Biden administration rule requiring larger companies to mandate that their workers get vaccinated against Covid-19 or submit to weekly testing by Jan. 4. A day later, the Labor Department said that it would delay that deadline until Feb. 9.
Pfizer vaccine in younger children. The company said that a low dose of its coronavirus vaccine did not produce an adequate immune response in 2- to 5-year-olds in ongoing clinical trials. The setback threatens to keep the vaccine from younger children for longer than many had hoped.
On this issue, the results are mixed. Surveillance data from British Columbia and Quebec suggest that a longer dosing interval improves the effectiveness of the vaccine, according to a study that has not yet been peer-reviewed. That is, people who had a longer stretch between doses had a lower risk of becoming infected than those who opted for less time.
But studies from Britain haven’t been as clear-cut. One found a modest benefit of delaying the second dose. Two other studies didn’t find any effect.
The impact of dosing intervals on the risk of myocarditis is even less clear. In one study, which has not yet been peer-reviewed, researchers examined Ontario’s vaccine safety surveillance data and identified 297 cases of inflammation of either the heart muscle or the outer lining of the heart after vaccination in people 12 and older. Of those, 207 occurred after the second dose. The rates were higher among people who separated their vaccines by a month or less compared with those who waited six weeks or more.
Whether the vaccine will trigger excess myocarditis in 5- to 11- year-olds remains to be seen. So far, more than seven million doses of the vaccine have been administered to this age group in the U.S. and only 14 possible cases of myocarditis have been reported to the government.
The risk of myocarditis is far higher among teenage boys and young men: about 11 cases for every 100,000 males between ages 16 and 29 receiving a second dose, according to one study.
That worries Lisa Rollins, a software trainer in Fredericksburg, Virginia. Her son turned 12 in early December after receiving his first dose. She plans to wait six weeks to get him his second shot. He’s doing virtual learning for now, she and her husband work from home, and the rest of the family is fully vaccinated. So “his risk is pretty low,” Ms. Rollins said. “I think waiting a little bit longer makes sense for us.”
Scott Hensley, an immunologist at the University of Pennsylvania’s Perelman School of Medicine, points out that we also can’t yet quantify how much benefit children might get from waiting a few weeks. His children received their second doses four weeks after their first.
“If there was not a pandemic going on, the answer would be simple — longer duration would be better,” Dr. Hensley said. But “we are at a point in time in the United States where Omicron is going to sweep our nation and it’s going to probably sweep across the world. And so there has never been a better time to get vaccinated.”
It’s an argument that Dr. Ishal finds increasingly persuasive. Cases are surging in New York City. The city-run vaccination site in Queens where he took his daughters for their first shots booked second-dose appointments for three weeks out. Given what’s happening with Omicron, he may just keep that time slot.
“We’ll take all the protection we can get right now,” he said. “I think I just decided.”